A phase II trial of gemcitabine for metastatic neuroendocrine tumors

Cancer

Volumn 101, Issue 5, 2004, Pages 934-939

  Kulke, Matthew H ^a   Kim, Haesook ^a   Clark, Jeffrey W ^b   Enzinger, Peter C ^a   Lynch, Thomas J ^a   Morgan, Jeffrey A ^a   Vincitore, Michele ^a   Michelini, Ann ^a   Fuchs, Charles S ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Carcinoid; Gemcitabine; Neuroendocrine tumors; Pancreatic islet cell

Indexed keywords

DACARBAZINE; GEMCITABINE; STREPTOZOCIN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 4143098212     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20466     Document Type: Article

References (19)

1. DiBartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer. 1996;77:402-408.
2. Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol. 1991;30:519-522.
3. Faiss S, Pape U, Bohmig M, et al. Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689-2696.
4. Moertel C, Hanley J. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials. 1979;2:327-334.
5. Engstrom P, Lavin P, Moertel C, Folsch E, Douglass H. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol. 1984;2:1255-1259.
6. Moertel C, Lefkopoulo M, Lipsitz S, Hahn R, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519-523.
7. Bukowski R, Tangen C, Peterson R, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer. 1994;73:1505-1508.
8. Ramanathan R, Cnaan A, Hahn R, Carbone P, Haller D. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group. Ann Oncol. 2001;12:1139-1143.
9. Feldman J. Treatment of metastatic pheochromocytoma with streptozocin. Arch Intern Med. 1983;143:1799-1800.
10. Averbuch S, Steakley C, Young R, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109:267-273.
11. Kulke M, Kim H, Stuart K, et al. Phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. In press.
12. Ansell S, Pitot H, Burch P, Kvols L, Mahoney M, Rubin J. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001;91:1543-1548.
13. Burris H, Moore M, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
14. Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989;10:1-10.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1959;53:457-481.
16. Rivera E, Ajani J. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet cell carcinoma. Am J Clin Oncol. 1998;21:36-38.
17. Cheng P, Saltz L. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86:944-948.
18. McCollurn A, Kulke M, Ryan D, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. In press.
19. Bajetta E, Ferrari L, Procopio G, et al. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumors. Ann Oncol. 2002;13:614-621.